

Product Update:

mifepristone 200mg tablet and misoprostol 0.2mg vaginal tablets
combipack (Medabon[®]) (No. 913/13)

Sun Pharma

04 October 2013 (*Issued 10 October 2014*)

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

mifepristone tablet and misoprostol vaginal tablets combipack (Medabon[®]) is accepted for use within NHS Scotland.

Indication under review: for medical termination of developing intra-uterine pregnancy of up to 63 days of amenorrhoea.

For patients in whom mifepristone and misoprostol is an appropriate choice of therapy, Medabon[®] provides the two components in a single pack at a lower cost than the individual components.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 15 August 2013.

Chairman
Scottish Medicines Consortium